<DOC>
	<DOC>NCT01263808</DOC>
	<brief_summary>This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.</brief_summary>
	<brief_title>Cardiac Safety of Indacaterol</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy, nonsmoking Body mass index (BMI) 18.532 kg/m2 Body weight at least 50 kg Recent/concurrent use of concomitant medications (except acetaminophen) Recent participation in other clinical trials Recent donation or loss of blood History/presence of a range of medical conditions, including electrocardiographic (ECG) abnormalities, diabetes mellitus, hyperthyroidism and impaired renal function Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Indacaterol</keyword>
	<keyword>Moxifloxacin</keyword>
</DOC>